Related Experiment Video

Updated: Sep 26, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.6K

Multicentric Castlemans disease. Symptoms, diagnostics and therapy

Zdeněk Adam, Zdeněk Řehák, Zuzana Adamová

    Vnitrni Lekarstvi
    |April 23, 2022
    PubMed

    Insights

    Castleman disease (CD) is a rare blood disorder. This study outlines symptoms and presents international consensus criteria for diagnosing and treating idiopathic multicentric Castleman disease (iMCD).

    Area of Science:

    • Hematology
    • Oncology
    • Immunology

    Background:

    • Castleman disease (CD) encompasses diverse hematologic disorders characterized by lymph node enlargement.
    • CD presents as unicentric (UCD) or multicentric (MCD) forms.
    • MCD can be associated with human herpesvirus-8 (HHV-8) or be HHV-8-negative/idiopathic (iMCD).

    Purpose of the Study:

    • To report on the symptoms of idiopathic multicentric Castleman disease (iMCD).
    • To present the international consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
    • To outline international evidence-based treatment guidelines for iMCD.

    Main Methods:

    • Literature review and expert consensus.
    • Analysis of diagnostic and treatment data for iMCD.
    • Development of evidence-based guidelines.

    Main Results:

    • iMCD presents with a range of symptoms and can have poor outcomes.
    • International consensus criteria for diagnosing iMCD have been established.
    • Evidence-based treatment guidelines for iMCD are now available.

    Conclusions:

    • Accurate diagnosis and standardized treatment are crucial for managing iMCD.
    • The established criteria and guidelines aim to improve patient outcomes in iMCD.
    • Further research may refine understanding and treatment of this rare disorder.

    Keywords:
    Castleman diseasesiltuximab

    More Related Videos

    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

    Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

    Published on: February 10, 2023

    1.5K
    Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

    Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

    Published on: September 9, 2022

    3.9K

    Related Concept Videos

    Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

    Cardiomyopathy IV: Restrictive Cardiomyopathy

    Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
    53
    Chronic Kidney Disease III: Interprofessional Care01:28

    Chronic Kidney Disease III: Interprofessional Care

    Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
    92
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    48
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    267
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    41
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    73